Status:
RECRUITING
Translational Immunodiagnostics in Stroke (TrImS)
Lead Sponsor:
The University of Hong Kong
Conditions:
Acute Ischemic Stroke
Haemorrhagic Stroke
Eligibility:
All Genders
18-100 years
Brief Summary
In adult patients presenting to emergency departments within 24 hours of symptom onset with suspected acute stroke, we aim: 1. to identify early brain- and pathology-specific circulating, whole blood...
Detailed Description
Introduction Stroke is a leading cause of overall mortality, morbidity and disability worldwide. In 2010 it was the second leading cause of death whilst in 2019 it ranked third overall for disability...
Eligibility Criteria
Inclusion
- Patients eligible for enrolment include:
- Adults ≥18 years of age.
- Suspected acute stroke. Defined as either FAST-positive, or LAPSS-positive or ROSIER\>0
- Within 24 hours of symptom onset.
- Informed consent.
- Control subjects will be drawn from two groups:
- Non-neurologic patients who are matched with TIA and stroke cases (AIS, HS) for age, race, gender and smoking plus one or more of the following vascular risk factors: diabetes, hypertension, atrial fibrillation, hyperlipidaemia.
- Relatives or accompanying friends.
- Note that we will include and collect samples from the following cases if they present as suspected stroke and are recruited \<24 hours from symptom onset.
- Any central nervous system infection, i.e. meningitis or encephalitis in the past 30 days
- Any form of head trauma, stroke or intracranial haemorrhage in the past 30 days
- Known primary or metastatic cancer involving the brain
- Active cancer is defined as a diagnosis of cancer, within 6 months before enrollment, any treatment for cancer within the previous 6 months, or recurrent or metastatic cancer.
- Autoimmune diseases: such as lupus, rheumatoid arthritis, Crohn's disease, ulcerative colitis
- Active infectious diseases (e.g. HIV/AIDS, hepatitis C)
- Major surgery within three months prior to the index event
Exclusion
- Clear onset of acute symptoms \>24 hours.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 30 2025
Estimated Enrollment :
650 Patients enrolled
Trial Details
Trial ID
NCT05300997
Start Date
May 1 2022
End Date
May 30 2025
Last Update
June 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hong Kong University
Hong Kong, China